Caris Life Sciences, Inc.

New proceeds will bolster the nearly $170 million in funds Caris Life Sciences raised earlier this year as the company looks to expand the commercial reach of its precision medicine platforms. \n Caris Life Sciences bumped up the pricing of its IPO to raise more than $494.1 million in its Nasdaq debut—well over the range it first proposed last week, in the vicinity of $400 million.The Texas-based cancer testing company claimed a valuation of about $5.9 billion, while selling 23.5 million shares under the ticker \"CAI\" at $21 apiece. It had first offered stock between $16 and $18 before later increasing the price to between $19 and $20.Caris also said it granted a 30-day option to underwriters to purchase up to an additional 3.5 million shares at the IPO price. The offering is expected to close June 20. This morning, the company’s founder and CEO, David Halbert, rang the Nasdaq’s opening bell. The proceeds will bolster the nearly $170 million in funds it raised earlier this year, as the company looks to expand the commercial reach of its precision medicine platforms. Caris obtained an FDA approval last November for a multi-cancer companion diagnostic and tumor profiling test, dubbed MI Cancer Seek, which relies on whole exome and transcriptome sequencing to help match patients with specific therapies.Its other tests include the Caris Assure liquid biopsy for treatment selection and its MI Profile tumor sequencing platform. In its IPO prospectus, the company said its global case volume grew 26% annually in 2024 and by 31% year over year in the first quarter of 2025.Caris also reported total revenue of $412.3 million for the 2024 calendar year, up from $306.1 million the year before, alongside a net loss of $257.1 million. Following a slowdown in medtech IPOs during the past few post-COVID years, a number have posted upsized, nine-figure offerings in the past 12 months: EEG headset maker Ceribell raised more than $180 million; Kestra Medical collected about $202 million for its wearable defibrillator; and diabetes hardware company Beta Bionics ultimately netted nearly $235 million. Additionally, the previously public Australian transcatheter heart valve designer Anteris Technologies raised $88.8 million through a dual listing on the Nasdaq and ASX while transferring its registration to the U.S.

全球视野，深度视角各位亲爱的股东，大家早上好中午好晚上好！更快更全的更新在星球：<循因缉药 Elite>，加入方法如下。小编在这里！星球在这里！标题党一下，顺便，刚刚解散过的行业群也还在“IPO”中，欢迎加上面联系方式，咱们群里见。哦，麻烦说明下高就、贵姓哈。我们此前聊过，Caris Life  Science准备上市了，今天更新下进展。2025年6月17日，这个发行价终于是定下来了。根据公告，本次Caris将发行23,529,412股普通股，公开发行价格为每股21.00美元。此外，Caris还授予承销商30天的选择权，可按首次公开募股价格（扣除承销折扣和佣金后）额外购买最多3,529,411股普通股。以此计算，本次公开募股将募集约5.68亿美元。Caris表示，预计公司股票将于6月18日（今天）在纳斯达克交易，股票代码“CAI（菜？？？）”那么，大家觉得这个价格怎么样呢？END小编在这里！星球在这里！各位股东看了么？赞了么？转发了么？别忘了点赞。谢谢！所有内容均不作为投资建议，信息均来自公开资料，星球更新更快。近期文章：500人的大群说没就没2500万美元拿下DZD资产！生物梅里埃离纳米孔病原检测越来越近做ADC的ADC Therapeutics融资1亿美元转头裁员30%忠诚的23andMe终于迎回了缔造他的女王相关资料：注1：https://www.prnewswire.com/news-releases/caris-life-sciences-announces-pricing-of-initial-public-offering-302484552.html

Caris Life Sciences made its NASDAQ debut on Wednesday, posting 33% gains during its first day of trading that brought its valuation close to $8 billion — a roughly 55% higher market capitalisation than its original $5.1 billion goal. The massively upsized IPO suggests continued investor enthusiasm for the healthtech sector, and is also a win for the biotech industry; Caris is the only company with a platform that touches on drug development to go public this quarter. The firm uses next-generation sequencing and AI technologies to develop blood- and tissue-based cancer diagnostics, and also leverages the data it generates to fuel its therapeutic discovery engine.Caris' product portfolio includes MI Profile, a tissue-based molecular profiling solution that includes both immunohistochemistry protein expression testing; MI Cancer Seek, its FDA-approved companion diagnostic to identify cancer patients who may benefit from targeted therapies; Assure, a blood-based test designed to provide diagnostic, prognostic, and predictive utility for cancer care; and its target discovery platform, Caris Discovery, which has attracted partners such as Moderna, AbbVie, Xencor and Merck KGaA. IPO momentumCaris sold 23.5 million shares at $21 a piece to raise $494.1 million late on Tuesday. Its share price climbed to $28 during its trading debut Wednesday.Not only did the price point far exceed its initial expected range of $16 to $18, it also topped Caris' last-minute bumped-up proposal of $19 to $20 per share. The offering takes the crown for largest healthtech IPO for the quarter so far, both in terms of total raised and resulting company valuation.Two virtual care companies — Omada Health and Hinge Health — closed successful public listings earlier in the period. Omada made its trading debut on Friday after raising $150 million at a roughly $1.1 billion valuation, and Hinge is valued at about $3 billion after pocketing $437 million in its May offering.